Business
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
CULVER CITY, Calif., March 13, 2026--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform.
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":956,"height":317,"url":"https://media.zenfs.com/en/business-wire.com/8b1c7069e2fd6e98d4d5f21da43ce9d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/teb0LMzL5bgrtuGvRdWZuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8b1c7069e2fd6e98d4d5f21da43ce9d0","width":956,"height":317},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XZzrWokOETv95KwAmaPqbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE5MTI7aD02MzQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8b1c7069e2fd6e98d4d5f21da43ce9d0","width":956,"height":317}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Methods developed and validated to establish the "World Bank of NK Cells" from healthy donors and cancer patients","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient","length":170,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)","length":109,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)","length":96,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":747,"olType":false},{"type":"text","content":"CULVER CITY, Calif., March 13, 2026--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its ...